T he molecular pathways dictating effector cell differentiation from naive CD4 + T-cells are controlled by transcription factors that regulate the expression of lineage-specific genes. Several of these transcription factors act as pioneers and initiate large scale changes in genetic programs by altering the chromatin landscape to create accessible regions at promoters, enhancers, and locus-control regions (LCRs) 1 . Type-2 T-helper (Th2) cells are formed following the activation of naive CD4 + T-cells in the presence of IL-4, and are critical in helminth infections and allergic diseases including asthma 2 . IL-4 is known to activate the signal transducer and activator of transcription 6 (STAT6) 3 , which in turn induces expression of GATA3, a potent pioneer transcription factor that acts at the Th2-LCR, and Th2-cytokine promoters 4 . By enhancing the expression of IL-4, GATA3 enforces a positive feedback loop that stabilizes the Th2 lineage 2 . However, compared to the other T-helper effector lineages, our understanding of the mechanisms behind Th2 differentiation in vivo is incomplete. The role of the canonical IL-4/STAT6 pathway, which has been used in in vitro CD4 + T-cell polarization for many years, generated conflicting reports in vivo 5 , and STAT6-independent mechanisms of Th2 differentiation have been identified 4 .
The Th2 cytokine locus, which contains the Il4, Il5, and Il13 genes, is under the control of an LCR located within the 3′ end of the Rad50 gene 6 . In vivo-deletion studies have shown that mice lacking the Th2 LCR have significantly impaired Th2 cytokine secretion and do not develop severe asthma 7 . The Th2 LCR contains four functionally distinct DNase hypersensitive sites (HSs), of which three are Th2 specific: Rad50 (R) HS IV, V, and VII. RHS VII has been shown to be critical in forming a poised-chromatin structure, which initiates the long-range interactions between the LCR and the Th2-cytokine promoters 8 . RHS IV needs to have a transcriptionally active configuration promoted by SATB1 9 , while RHS V is needed to enhance the Il4 transcription through interactions with the Il4 promoter mediated by GATA3, OCT-1, and ETS-1 10 . In addition to the LCR, Th2 differentiation is controlled by a conserved silencer, downstream of the Il4 gene at the HS IV 11 . During Th1 differentiation, the transcription factor Runx3 associates with the Il4 HS IV silencer to block Il4 transcription 12, 13 . In addition, Runx3 attenuates the activity of GATA3 through direct interaction 14 .
Bcl11b functions both as a transcriptional repressor, when associated with the Nucleosome Remodeling and Deacetylase (Mi-2/NuRD) complex [15] [16] [17] , and as a transcriptional activator, when associated with the p300 histone acetyl transferase 18 . Bcl11b is expressed in thymocytes starting at the DN2 stage, playing major roles in the commitment to T-cell lineage. It further controls the beta and positive selection of thymoctes [19] [20] [21] [22] [23] and is critical for the development of T-regulatory cells and iNKT cells [24] [25] [26] ( and reviewed in ref. 27 ). Bcl11b also controls cytotoxic T-cell function in bacterial and viral infections 28, 29 , and is expressed in naive and effector CD4 + T-cells 23, 28 . Bcl11b blocks GATA3 and IL4 in pathogenic Th17 cells during experimental autoimmune encephalomyelitis (EAE), thus controlling the plasticity of Th17 cells 30 . Bcl11b is also critical for type-2 innate lymphoid cell (ILC2s) development 31, 32 , maintenance of their program and identity, as well as for the repression of type-3 ILC program in ILC2s 33 .
Here, we ascertain a new role for Bcl11b in the network of transcription factors that control differentiation of the Th2 lineage in vivo. We identified major defects in the capacity of Bcl11b-deficient T-helper cells to differentiate into Th2 cells in vivo, causing diminished responses to helminth infection and reduced severity of asthma. By evaluating the genome-wide binding of Bcl11b and comparing the changes in the transcriptome and chromatin accessibility, we established that Bcl11b-deficient Thelper cells fail to upregulate GATA3, express Runx3, and have enhanced chromatin accessibility at the Il4 HS IV silencer, but reduced accessibility at Th2-cytokine LCR and Th2-cytokine promoters. We position Bcl11b as a direct negative regulator of Runx3-gene expression, by binding and blocking two upstream enhancers in Th2 cells and naive CD4 + T-cells. In addition, we found the Bcl11b binding to conserved cis-regulatory sites located in the introns and downstream to the Gata3 locus. Thus, the reduction in GATA3, combined with increased Runx3 activity at the accessible Il4 HS IV silencer and diminished IL-4 expression in the absence of Bcl11b, resulted in diminished chromatin opening at the Th2 LCR, and at the Il13 and Il5 promoters, followed by reduced Th2 cytokine expression. This cements Bcl11b as an important transcription factor in Th2 lineage licensing. In addition, Bcl11b-deficient Th2 cells showed abnormal expression of alternate-lineage genes, including those of Th17, Th1, and innate cells.
Results

Removal of Bcl11b in T-cells attenuates allergic asthma.
Our previous studies have shown that in mice induced with EAE, the absence of Bcl11b in mature T-cells caused increased plasticity of Th17 cells by acquisition of GATA3 and IL-4 30 . However, we found that Bcl11b plays a critical role in ILC2s, promoting their program and preserving their identity 33 . Given these results, we investigated the role of Bcl11b during a house dust mite (HDM)-induced asthma, a Th2-mediated disease. For these studies, we used Bcl11b fl/fl dLck-iCre mice, whose Cre-recombinase is under the distal Lck promoter, which becomes active only in mature T-cells 34 . We have previously shown that this late-deleting-Cre system removes Bcl11b in~80% of the mature CD4 + T-cells, and does not cause the removal of Bcl11b in DP and single-positive thymocytes, allowing T-cells to reach normal maturity 28 .
Following sensitization and challenge with HDM extract derived from Dermatophagoides pteronyssinus ( Supplementary  Figure 1a) , we found that Bcl11b fl/fl dLck-iCre mice developed less severe lung pathology than wild-type (WT) mice, with substantially reduced leukocyte infiltration (Fig. 1a) . Eosinophils, which are recruited to the lung during HDM-induced asthma, were present in significantly lower numbers in Bcl11b fl/fl dLckiCre mice (Fig. 1b and Supplementary Figure 1b) . The frequency and absolute numbers of CD4 + T-cells were also significantly reduced in the lungs of Bcl11b fl/fl dLck-iCre mice induced with HDM-asthma (Fig. 1c, d ). The frequency of CD4 + T-cells within the mediastinal lymph nodes (mediLNs) was also reduced in Bcl11b fl/fl dLck-iCre mice, however not as severely as in the lung (Supplementary Figure 1c) . Taken together, these results demonstrate that the removal of Bcl11b from mature T-cells results in reduced pulmonary pathology after induction of allergic asthma, which was associated with reduced lung eosinophils and CD4 + T-cells.
Absence of Bcl11b in T-cells reduces anti-helminth response.
Given the chronic nature of allergic asthma, we investigated the immune response to infection with intestinal helminth H. polygyrus bakeri, known to induce a strong primary Th2 response. Unlike many parasitic nematodes that migrate to other mucosal sites, the entire life cycle of H. polygyrus bakeri occurs within the gastrointestinal tract 35 . We found that on day 10 post inoculation (p.i.) (Supplementary Figure 2a) , the Bcl11b fl/fl dLck-iCre mice had a significant increase in fecal egg burden, compared to WT mice (Fig. 2a) . The Flow cytometry analysis showed a reduction in the absolute numbers of CD4 + T-cells in the mesenteric lymph nodes (mLNs) and Peyer's patches (PPs) of Bcl11b fl/fl dLck-iCre mice (Fig. 2b, c) , however the numbers were increased in the small intestine lamina propria (SILP), as were their relative frequencies ( Fig. 2d and Supplementary Figure 2f-g ). This increase in SILP CD4 + T-cells was found to be related to the upregulation of CCR9 on Bcl11b-deficient CD4 + T-cells (Supplementary Figure 2h) . Thus, despite the increased abundance of CD4 + T-cells in the SILP, the fecal egg burden was higher in Bcl11b fl/fl dLck-iCre mice compared to WT mice, indicating a less robust Th2 response.
Bcl11b-deficient T-helper cells downregulate Th2 mRNAs. To establish the mechanisms associated with reduced Th2 response in asthmatic and helminth-infected Bcl11b fl/fl dLck-iCre mice, we next performed RNA-sequencing on CD4 + T-cells isolated from: (1) mediLNs of asthma-induced Bcl11b fl/fl dLck-iCre and WT mice, and (2) mLNs of helminth-infected mice, and found that a large number of mRNAs significantly changed (Supplementary Figure 3) . In regard to the Th2 program, we found that the levels of mRNAs for Gata3 and the Th2 cytokines Il4, Il5, and Il13 were all significantly reduced in the CD4 + T-cells from Bcl11b fl/fl dLck-iCre mice (Fig. 3a) . We also detected an increase in several Th17 mRNAs, namely for Rorc and Ccr6, with Il17a, and Il23r showing a similar trend (Fig. 3b) . Given that Bcl11b fl/fl dLck-iCre mice show a less robust Th2 response, we further enriched the IL-4-secreting CD4 + T-cell population and even in these conditions, the levels of Il4, Il13, and Gata3 mRNAs were still significantly reduced in the absence of Bcl11b, with a similar trend in Il5 mRNA (Fig. 3d) . In addition, the previously observed increases in Th17 mRNAs, including for Rorc, Ccr6, Il17a, and Il23r, were amplified in the Bcl11b-deficient IL-4 + CD4 + T-cell population (Fig. 3e) . While the levels of Ifng transcripts in the total CD4 + T-cell population were approximately equal, there was an increase in Ifng mRNA levels in the IL-4-enriched CD4 + T-cell population of the Bcl11b fl/fl dLck-iCre mice, compared to WT mice (Fig. 3c, f) . Tbx21 mRNA encoding the Th1 signature transcription factor T-bet was upregulated as well, both in the IL-4-enriched CD4 + T-cell population and total CD4 + T-cells (Fig. 3c, f) . Finally, we found no change in Gfi1 mRNA (Fig. 3g ), known to be downregulated in Bcl11b-deficient ILC2s 33 , or Zbtb7b (Fig. 3g) , previously found upregulated in Bcl11b-deficient DP thymocytes 36 .
These results, taken together, suggest that, in the context of Th2-mediated diseases, Bcl11b is necessary for Th2 cytokine and Gata3 gene expression, as well as for the repression of critical Th17 and Th1 cell genes.
Reduction in Th2 program is caused by intrinsic defects. We next evaluated the protein levels of GATA3 and Th2 cytokines in the T-helper cells of mice induced with HDM-asthma or infected with helminths. We found that the frequencies of GATA3 + IL-4 + , GATA3 + IL-5 + , and GATA3 + IL-13 + CD4 + T-cells in the lungs of asthma-induced Bcl11b fl/fl dLck-iCre mice were reduced, as were the frequencies of GATA3 + , IL-4 + , IL5 + , and IL-13 + CD4 + T-cells. (Fig. 4a, b) . When evaluating H. polygyrus bakeri-infected mice, we noticed a similar reduction in Th2 cytokines and GATA3 within the CD4 + T-cells from the mLNs (Fig. 4c, d ) and SILP ( Supplementary Figure 4a-c) . To further determine the ability of Bcl11b-deficient T-helper cells to differentiate in vivo, we separated the GATA3 + CD4 + T-cells from the mLNs of helminth-infected mice into GATA3 hi and GATA3 lo populations, and also gated separately on Bcl11b − and Bcl11b + CD4 + T-cells (Fig. 4e, f) . The GATA3 hi /GATA3 lo ratio was 2.6 within the CD4 + T-cell population of WT mice (Fig. 4e, f) , while this ratio was only 0.52 in the Bcl11b-deficient CD4 + T-cell population of Bcl11b fl/fl dLck-iCre mice (Fig. 4e, f) .
Even the small population of Bcl11b + "escaper" CD4 + T-cells from Bcl11b fl/fl dLck-iCre mice had a similarly reduced ratio of GATA3 hi /GATA3 lo cells (Fig. 4e, f) , likely due to the overall reduction in IL-4. Within the GATA3 hi population of WT mice, the frequency of IL4 + cells was around 80%. This frequency was reduced by nearly half in both the Bcl11b − and Bcl11b + GATA3 hi cells of Bcl11b fl/fl dLck-iCre mice (Fig. 4e, f) . The frequency of IL-4 + cells within the GATA3 lo cells was only onethird of the GATA3 hi cells in the WT mice, and was further reduced in both the Bcl11b − and Bcl11b + cells of Bcl11b fl/fl dLckiCre mice (Fig. 4e, f) . These results suggest that (1) Bcl11b-deficient CD4 + T-cells are unable to completely differentiate into the Th2 lineage, and (2) even those cells that reach high levels of GATA3 cannot produce normal levels of IL-4 in the absence of Bcl11b. Importantly, the upregulation of the Rorc and Tbx21 mRNAs was not reflected at protein level ( Supplementary Figure 5a- To establish whether the reduction in Gata3 and IL-4 levels in Bcl11b − CD4 + T-cells is cell intrinsic, we generated mixed bonemarrow chimeras. Lethally irradiated recipient CD45.1 mice were reconstituted with cells from Bcl11b fl/fl (CD45.1/2) and Bcl11b fl/fl dLck-iCre (CD45.2) mice at a 1:1 ratio. Following reconstitution, the recipient mice were infected with H. polygyrus bakeri. Our results show that even in conditions in which Bcl11b + cells are present in equal numbers to Bcl11b − cells, GATA3 and IL-4 levels remained reduced in the Bcl11b − cells (Fig. 4g, h ), suggesting that these alterations are intrinsic.
These results demonstrate that in the absence of Bcl11b, CD4 + T-cells have an altered ability to differentiate into Th2 lineage properly in vivo, with diminished GATA3 and Th2 cytokine levels, caused by intrinsic defects.
Bcl11b binding at Th2 cytokine locus and Gata3. To further determine if Bcl11b directly mediates the observed changes in the Th2 program, we performed Bcl11b ChIP-seq on CD4 + T-cells from the mLNs of H. polygyrus bakeri infected mice. Using the MEME-ChIP motif analysis software 37 , we established the conserved binding motifs for Bcl11b, of which the top two are shown (Fig. 5a ). The first identified motif is a known Ets-1 binding motif, while the second motif, identical to a previously published Bcl11b binding site in striatal neuronal cells 38 , is a Runx binding motif 39 . Bcl11b binding sites were found to have increased presence at regions greater than 5 kb from the TSS (Fig. 5b) , suggesting that, overall, Bcl11b may normally act through distal regulatory elements, such as enhancers and silencers, rather than through promoters.
Among the Th2 genes, the most striking finding was the fact that Bcl11b did not bind to Il4, Il13, or Il5 promoters or to the Th2 LCR located within Rad50 gene (Fig. 5c ). However, Bcl11b bound to the Il4 HS IV silencer, located downstream of the 3′ end of the Il4 gene (Fig. 5c ), suggesting that Bcl11b may be necessary to limit the accessibility of Il4 HS IV silencer in Th2 cells. In addition, we found Bcl11b binding to conserved intronic sites within the Gata3 locus ( Fig. 5c ), as well as to other conserved non-coding regions downstream of the Gata3 locus (Fig. 5e ), which suggests that Bcl11b is potentially involved in direct regulation of Gata3 gene expression. Bcl11b regulates chromatin opening at Th2 cytokine locus. We next performed the Assay for Transposase-Accessible Chromatin and sequencing (ATAC-seq) to evaluate the changes in chromatin accessibility 40 in CD4 + T-cells isolated from the lung of Bcl11b fl/fl dLck-iCre and WT mice with HDM-induced asthma (Fig. 6 ). We identified over 60,000 accessible regions in CD4 + T-cells from either WT or Bcl11b fl/fl dLck-iCre mice. Of these, 9516 were differentially accessible between the two groups ( Fig. 6a ).
The majority of differentially accessible regions (~65%) were unique to Bcl11b-deficient cells, while relatively few (~8%) were unique to WT cells (Fig. 6b ). This profile suggests that in these cells, Bcl11b plays a larger role in restricting chromatin accessibility than in opening it. Furthermore, using Genomic Regions Enrichment of Annotations Tool (GREAT) 41 , we found that the differentially accessible regions unique to one group were more likely to be found further away from the TSSs, while those regions common to both groups had a higher probability of being found closer to the TSSs (Fig. 6c ). This suggests that Bcl11b is more likely to regulate enhancers and silencers rather than promoters, similarly to what we found for its binding relative to the TSSs (Fig. 5b) . We focused on genes related to Th2 response, and found that the Rad50 HS 5 (RHS V) within the Th2 cytokine LCR had significantly reduced accessibility in Bcl11b-deficient T-helper cells compared to WT cells from asthma-induced mice (Fig. 6d) , despite the fact that Bcl11b did not bind to this region (Fig. 5c ). In addition, the accessibility at Il5 and Il13 promoters was reduced in the absence of Bcl11b (Fig. 6e, f) , again without Bcl11b binding at these promoters (Fig. 5c ). However, there was a significant increase in the chromatin accessibility at the Il4 HS IV silencer both in Th2 cells and in naive CD4 + T-cells (Fig. 6g) , where Bcl11b was found to bind (Fig. 5c) .
These results show that the absence of Bcl11b in T-helper cells in Th2 conditions in vivo causes a failure in chromatin opening at the Th2 LCR, Il5 and Il13 promoters, and an inability to reduce the chromatin accessibility at the Il4 HS IV silencer, including in naive cells.
Other genes regulated by Bcl11b in Th2 cells. As shown above mRNAs for Th17 and Th1 genes were upregulated in the absence of Bcl11b. While there was no binding of Bcl11b at Rorc, Tbx21, IL23R, and CCR6 loci, Bcl11b did bind to conserved noncoding regions adjacent to Ifng and Il17 loci (Supplementary Figure 6a- Figure 6d) . Bcl11b directly associated with non-coding regions in close proximity to these genes ( Supplementary Figure 6e) , as well as within non-coding regions in the Spi1 gene, encoding PU.1 transcription factor, which, was however not upregulated at the mRNA level (Supplementary Figure 6f ). These results suggest that Bcl11b directly restricts expression of Ifng and Il17 and of several myeloid and NK genes in Th2 cells.
Bcl11b-deficient T-helper cells have elevated Runx3. As shown above, absence of Bcl11b caused increased chromatin accessibility at the Il4 HS IV silencer. In Th1 cells, Runx3 and T-bet synergistically bind to Il4 HS IV silencer 12 to repress Il4 transcription, however Runx3 alone is sufficient to repress Il4 in Th1 cells 11, 12 , even though both Runx3 and T-bet are needed to promote Ifng expression. Both Runx3 and Tbx21 mRNAs were significantly increased in the absence of Bcl11b (Figs. 3c, f and 7a ). However, while T-bet protein remained unchanged (Supplementary Figure 5a) , Runx3 protein was considerably upregulated in CD4 + T-cells from both helminth-infected and naive Bcl11b fl/fl dLck-iCre mice ( Fig. 7b-d ). However Runx3 expression was not upregulated in CD4 SP thymocytes of Bcl11b fl/fl dLck-iCre mice, and was expressed at equivalent levels to WT mice in CD8 SP thymocytes (Supplementary Figure 7 ), demonstrating that the phenotypes observed in the periphery are unlikely to be developmental in origin. Given that Runx3 is known to associate with the Il4 HS IV silencer to block Il4 transcription in Th1 cells 12 , we investigated whether the increased Runx3 in the absence of Bcl11b resulted in enhanced Runx3 binding to the Il4 HS IV silencer by performing Runx3 ChIP-qPCR. We indeed found elevated Runx3 binding to the more accessible Il4 HS IV silencer in CD4 + T-cells from naive and helminth-infected Bcl11b fl/fl dLck-iCre mice compared to WT (Fig. 7e) . Together, these results show that in the absence of Bcl11b, Runx3 levels are elevated, and the available Runx3 binds to the more accessible Il4 HS IV silencer both in CD4 + T-cells of helminth-infected and naive mice.
Bcl11b directly binds to and represses Runx3 gene expression. Given the elevated Runx3 levels, we next examined the Bcl11b ChIP-seq data and found enrichment of Bcl11b binding to two conserved non-coding regions, namely −39 kb and −18 kb upstream of the Runx3 TSS in CD4 + T-cells from naive and helminth-infected mice (Fig. 7f) . To further evaluate the chromatin activity at these sites, we performed ChIP-seq for H3K27ac, a histone modification known to be associated with active enhancers and promoters of actively transcribed genes 42 . Absence of Bcl11b caused increased H3K27ac at both the −39 kb and −18 kb regions (Fig. 7f) , suggesting that Bcl11b directly restricts expression of Runx3 by binding to and deactivating upstream Runx3 conserved enhancers in CD4 + T-cells. Further supporting our results is a recent publication in which deletion of the −39 kb cis-regulatory region bound by Bcl11b diminished the activity of a Runx3-reporter in CD8 SP thymocytes 43 . We also performed Bcl11b ChIP-seq in CD8-enriched thymocytes (mainly DP and CD8 SP thymocytes) and found Bcl11b binding at the −39 kb, −21 kb, and −18 kb cis-regulatory conserved sites, as well as at the P1 promoter (Fig. 7f) , critical for expression of Runx3 in CD8 + T-cells 44 . Thus, in thymocytes, Bcl11b binds to the cis-regulatory regions located at −39 kb, −21 kb, and −18 kb and to the P1 promoter (Fig. 7f) , while in naive and Th2 CD4 + T-cells Bcl11b binds only to the −39 kb and −18 kb conserved sites (Fig. 7f) .
Finally, we evaluated Runx3 in CD4 + T-cells of mixed bonemarrow chimeric mice infected with H. polygyrus bakeri. We found that Runx3 was upregulated only in the CD4 + T-cells which had Bcl11b removed and not in WT cells (Fig. 7g, h) , demonstrating that the upregulation of Runx3 in the absence of Bcl11b is intrinsic.
Thus these results demonstrate that Bcl11b directly restricts expression of Runx3 in Th2 cells and in naive CD4 + T-cells by binding to and deactivating upstream Runx3 enhancers.
Discussion
In this study, we demonstrate that Bcl11b plays a critical role in the differentiation of Th2 cells in vivo. Bcl11b has been previously shown to repress GATA3 and IL-4 in Th17 cells during EAE 30 . In addition, Bcl11b −/− CD4 + T-cells were shown to differentiate normally into Th2 cells in vitro, with their polarization being even slightly enhanced, compared to WT CD4 + T-cells 30 . However, in ILC2s, which are functionally similar to Th2 cells, Bcl11b was needed to sustain key type 2 transcription factors and cytokines and to block the ILC3 program 33 . We report here that Bcl11b is a critical transcription factor for licensing Th2 differentiation in vivo. Specifically, in response to allergeninduced asthma and intestinal helminth infection, CD4 + T-cells of Bcl11b fl/fl dLck-iCre mice failed to efficiently differentiate into Th2 cells, despite the fact that they expanded normally. Consequently, Bcl11b fl/fl dLck-iCre mice had reduced pulmonary pathology associated with the induction of allergic asthma, while having increased fecal egg burden following helminth infection. Transcriptome, chromatin accessibility and ChIP-seq analyses revealed the mechanisms by which Bcl11b regulated Th2 cell differentiation in vivo. In addition to the Th2 cytokines, GATA3 expression was reduced both at protein and mRNA levels. GATA3 has been shown to be indispensable for the initiation and propagation of Th2 differentiation 45 . The reduction in GATA3 was similar to the defects we previously found in the absence Bcl11b in ILC2s 33 , where, in addition, Gfi1 and Rora were also downregulated. The reduction in GATA3 in ILC2s was shown to be dependent on diminished Gfi1 expression. However, we did not find any changes in Gfi1 expression in Bcl11b-deficient Th2 cells, suggesting that the control of Gfi1 by Bcl11b is cell-type 46 . The Th2 LCR RHS V enhances Il4 transcription through interactions with the Il4 promoter, with GATA3 playing a central role in this process 10 . Bcl11b-ChIP-seq analysis showed no binding of Bcl11b at Th2-LCR, or Th2-cytokine promoters in Th2 cells; however, ATAC-seq showed reduced chromatin accessibility at the Th2 LCR RHS V and at the Il5 and Il13 promoters in the absence of Bcl11b. Thus the reduction in accessibility can be related, at least in part, to the decreased GATA3 levels in the absence of Bcl11b. In addition to the Th2 LCR and Il4 promoter, Il4 expression is also regulated through the Il4 HS IV silencer, which functions to repress Il4 expression in Th1 cells in vivo 11, 12 . A second defect of Bcl11b − T-helper cells during Th2 response was the high chromatin accessibility at the Il4 HS IV silencer, much more than in WT Th2 cells, similar to Th1 cells. This increase was also seen in the naive state. We found that Bcl11b directly binds to Il4 HS IV silencer in naive and CD4 + T-cells of mice infected with helminths, demonstrating that Bcl11b plays a critical role in directly limiting Il4 HS IV silencer accessibility in Th2 and naive CD4 + T-cells. Previous studies have demonstrated that Runx3, normally expressed in Th1 cells and CD8 + T-cells, binds to the Il4 HS IV silencer in Th1 cells and represses Il4 expression 12 . In relation to this, Bcl11b − T-helper cells from naive mice as well as from mice infected with helminths, had a third defect: showing a major elevation in Runx3 levels compared to Bcl11b-sufficient cells. In addition, Runx3 showed increased association with the Il4 HS IV silencer in both Bcl11b − CD4 + Tcells from naive and helminth-infected mice. Interestingly, the second motif that we identified as being bound by Bcl11b, "ACCACA", appears to be a Runx binding motif 39 . Thus, absence of Bcl11b results in availability and increased accessibility of Il4 HS IV silencer and elevated Runx3, which now can bind at the silencer. This, together with reduced levels of GATA3 cause diminished Il4 expression and reduced ability to efficiently differentiate into Th2 lineage in vivo.
Runx3 has also been shown to be important in ILC1 and ILC3 development, but not in ILC2 development 44 . In ILC3s, Runx3 positively regulates Rorc expression, which in turn increases the expression of Ahr 44 . It remains to be established whether in Bcl11b-deficient ILC2s, Runx3 is derepressed in a manner similar to Bcl11b − T-helper cells, which then may also contribute to the shift from ILC2 to ILC3 program 33 , a possibility which also exists in iNKT cells, where the absence of Bcl11b caused derepression of iNKT17 genes and reduction of the other iNKT cell subset genes 26 .
The disparities between the actions of Bcl11b on Th2 differentiation in vivo and in vitro have been of particular interest to us. We speculate that the constant supply of exogenous IL-4 during in vitro polarization is key to the observed changes, as previous reports have shown that certain defects in Th2 differentiation, such as those observed related to Notch signaling, can be compensated for in this way 4, 47 . It is possible that by providing constant, high amounts of exogenous IL-4 during the in vitro All statistical values in this figure were calculated using Student's t-test except for panel a, which was calculated using DESeq2 analysis software. All error bars shown in this figure are of standard deviation polarization, a Bcl11b-deficient cell is able to gradually overcome its defect in IL-4 production and begins upregulating GATA3 to a level sufficient to compensate the defect, and the excess in Runx3 is eventually overcame, allowing for the stabilization of the Th2 lineage in vitro.
We found that Bcl11b binds to several conserved cis-regulatory regions upstream of Runx3, namely at −39 kb, −21 kb, and −18 kb, as well as to the P1 promoter in CD8-enriched thymocytes, while in naive and Th2 CD4 + T-cells, it only bound to the −39 kb and −18 kb sites. Our finding that removal of Bcl11b results in enrichment of H3K27ac at the −39 kb and −18kb sites suggests that Bcl11b inactivates these enhancers in Th2 cells and likely in naive CD4 + T-cells. Very recently, in addition to our findings, Bcl11b was found to bind to the Runx3 cis-regulatory regions −39 kb and −21 kb sites in total thymocytes 43 . When these regions were deleted, a reduction in Runx3-reporter expression was observed in CD8 SP thymocytes, indicating that these regions act as enhancers for Runx3 in CD8 SP thymocytes 43 , and supporting the idea that in naive and Th2 cells, Bcl11b inactivates Runx3 enhancers, thus blocking its expression. It remains to be established whether Bcl11b binds to these Runx3 cis-regulatory regions in DP, CD4 SP thymocytes, and/or CD8 SP thymocytes, given that the ChIP-seq analysis was conducted in total thymocytes 43 , and in CD8-enriched thymocytes (this study). Interestingly, Thpok was also found to bind to the −39 kb and −21 kb sites in total thymocytes 43 . We did not find any changes in Thpok mRNA levels in the absence of Bcl11b in Th2 cells. Thus Runx3 repression in mature naive and Th2 CD4 + T-cells requires Bcl11b, and Thpok alone is likely not sufficient to exert this function. However, Thpok is essential in blocking Runxdependent differentiation toward CD8 lineage 48 . We did not notice any increase in CD8 + T-cells versus CD4 + T-cells as a consequence of Runx3 upregulation, likely due to the fact that removal of Bcl11b occurred after commitment to CD4 SP and CD8 SP thymocytes. In addition, CD8 expression was not detected in CD4 + T-cells. It remains to be established how Bcl11b regulates Runx3 in Th1 cells and CD8 + T-cells, where Runx3 is expressed 49 .
Similar to ILC2s, in Th2 cells, Bcl11b is also required to repress type 3 program including Rorc and Il17, however different from ILC2s, the proteins could not be detected in Bcl11b − Th2 cells, thus unlikely to participate in the phenotype. Tbx21 and Ifng mRNAs, but not proteins, were also upregulated. Except for Il17, Ifng, and Runx3, Bcl11b did not bind any other Th17 or Th1 loci or adjacent non-coding regions.
Bcl11b also repressed expression of several myeloid genes, including those encoding Cd11b, Cd11c, and Fc receptors, as well as of some killer cell lectin-like receptors and also bound to cisregulatory regions within or upstream of these genes, suggesting that Bcl11b may directly repress their expression in differentiating Th2 cells.
In conclusion, we established here that the absence of Bcl11b in naive and during Th2 response in vivo results in derepression of Runx3, as well as provision of access for Runx3 to the Il4 HS IV silencer. These events, together with reduced GATA3, caused reduced chromatin accessibility at Th2 LCR, and Th2 gene promoters, further resulting in reduced Th2 differentiation. These results together suggest that Bcl11b primes naive CD4 + T-cells in such a way to be permissive for Th2 differentiation, and absence of Bcl11b causes a failure in efficient licensing of Th2 lineage.
Methods
Mice. Bcl11b fl/fl dLck-iCre mice on a C57BL/6 were previously described 28 . All mice were raised and housed in pathogen-free conditions in the University of Florida Animal Facilities except mice infected with H. polygyrus, which were transferred to a BSL2 facility prior to infection. All experiments were conducted on 8-12-week-old male and female mice. All mouse work was approved by the University of Florida Institutional Animal Care and Use Committee. No statistical methods were used to predetermine sample size.
Induction of allergic asthma by HDM extract. 8-12-week-old mice were sensitized to house-dust-mite antigen by seven intraperitoneal injections of 100 μL PBS containing 50 µg HDM extract (D. pteronyssinus, Greer Labs) on days 1, 3, 5, 7, 9, 11, and 13. Then, on days 25, 26, and 27, mice were challenged intranasally (i.n.) with 20 μL PBS containing 50 µg HDM extract. Mice were anesthetized with isoflurane prior to each i.n. challenge. Mice were sacrificed on day 29.
Lung digestion for isolation of leukocytes. Lungs were initially perfused through the right ventricle with 10 mL cold PBS. The lungs were then excised and placed in a C tube (Miltenyi Biotech) containing 5 mL cold PBS and subsequently minced on a gentleMACS Dissociator (Miltenyi Biotech). The lungs were then digested for 45 min at 37°C with the addition of 0.2 Wünsch units/mL of Liberase TM (Roche) and 0.15 mg/mL DNase I (Roche). Digested tissue was filtered through a 70-μm strainer and washed with complete RPMI. Epithelial cells were removed by density separation using a 30%/70% discontinuous Percoll gradient.
Helminth infection. 8-12-week-old mice were infected with H. polygyrus via oral gavage with 200 μL water containing 200 L3 larvae. Fecal pellets were collected immediately before euthanasia on day 12 post infection, with the eggs/g feces serving as a readout of overall worm fitness.
Isolation of leukocytes from the SILP. Small intestinal lamina propria preparation methodology was adapted from previous study 50 . Small intestines were flushed with cold PBS and PPs were removed and set aside. Tissue was cleaned and washed once with 5 mM DTT and thrice with 5 mM EDTA. SILP was then digested at 37°C for 30 min with 0.2 Wünsch units/mL of Liberase TM (Roche) and 0.1 mg/mL DNase I (Roche). Digested tissue was filtered through a 70-μm strainer and washed with complete RPMI. Remaining epithelial cells were removed by density separation using a 30%/70% discontinuous Percoll gradient.
Isolation of CD4 + T-cells from total leukocytes. For leukocytes prepared from lung tissue, CD4 + T-cells were purified by FACS, using a BioRad S3e Cell Sorter. For cells from the mesenteric and mediastinal lymph nodes, CD4 + T-cells were purified using Dynabeads Untouched Mouse CD4 Cell kit (Invitrogen).
Enrichment of IL-4 + CD4 + T-cells from total leukocytes. Labeling and enrichment of IL-4 + cells from pre-negatively selected CD4 + T-cells was performed using the Mouse IL-4 Secretion Assay kit from Miltenyi Biotech (#130-00-515). Enrichment was verified to be 40%, by flow cytometry.
RNA-Seq. RNA was extracted from CD4 + T-cells purified from the mLNs of H. polygyrus infected mice or the mediLNs of asthmatic mice using RNeasy Plus Micro Kit (QIAGEN). cDNA libraries were prepared off-site and sequencing was performed on a NextSeq 500. Sequencing reads were processed and analyzed using a custom pipeline. Fastq files were initially trimmed using seqtk 51 . Quality of the fastq files were assessed via FastQC 52 . Trimmed reads were aligned to the mouse (mm10) genome using Hisat2 53 . Htseq 54 was utilized to obtain transcript counts for each sample, which were then run through DeSeq2 55 for differential analysis.
ATAC-Seq. DNA from 50,000 CD4 + T-cells was extracted and processed for ATAC-Seq as described by others 40 . Library quality and adapter dimer contamination was assessed on a Bioanalyzer (Agilent, #5067-4626). Libraries were run as PE75 on a NextSeq 500. Data analysis was performed using a custom pipeline based on a modified version of a previously published method 56 . Fastq files were initially trimmed using Trimmomatic 57 , then read quality was assessed using FastQC as before 52 . Reads were aligned to the mouse (mm10) genome using Bowtie2 58 and the resulting SAM file was pruned (Q > 30), converted into BAM format, and sorted using SAMtools 59 . Duplicate reads were identified and removed using Picard tools 60 . Peaks were called and bedgraph files were prepared using MACS2 peak calling software 61 . Bedgraph files were then visualized using Integrative Genomics Viewer (IGV) 62 .
Bcl11b ChIP-Seq. ChIP-Seq against Bcl11b was performed on CD4 + T-cells using the SimpleChIP Enzymatic Chromatin IP Kit from Cell Signaling Technologies (#9003), following their recommended protocol up to the library preparation with the following alterations: (1) 10 7 cells were used in place of 4 × 10 7 ; (2) formaldehyde fixation was performed in 1 mL; (3) Buffer A and Buffer B steps were all performed in 1 mL; (4) 2 μl of 1:10 diluted Micrococcal nuclease was determined to give the optimum digestion results by titration; (5) cocktail of two anti-Bcl11b antibodies were used (8 μg ab18465 and 3 μg of CST #12120 per ChIP); (6) final DNA purification was performed by phenol:chloroform:isoamyl alcohol extraction with MaXtract high density columns (Qiagen #129046). Libraries were prepared using NEBNext DNA Library Kit (NEB, #E7645), with quality being determined as above. Libraries were run as SE75 on a NextSeq 500. Fastq analysis performed as with ATAC-Seq, but with single-end rather than paired-end settings.
H3K27ac ChIP-Seq. ChIP-Seq against H3K27ac was performed on 100,000 CD4 + T-cells isolated from the lungs of HDM asthma-induced Bcl11b fl/fl dLck-iCre and Bcl11b fl/fl mice using the Low Cell ChIP-Seq kit from Active Motif (#104895), following their recommended protocol scaled to 100,000 cells. The antibody used was acetyl-histone H3 (Lys27) (D5E4) XP® Rabbit mAb from Cell Signaling Technologies (#8173) at the recommended 1:100 dilution. Libraries were run as SE75 on a NextSeq 500. Fastq analysis performed as with Bcl11b ChIP-Seq.
Mixed bone-marrow chimeras. To generate mixed bone-marrow chimeras, CD45.1 mice were irradiated twice with 500 rads, 4 h apart, on the same day prior to reconstitution with cells from CD45.1/CD45.2 Bcl11b fl/fl mice and CD45.2 Bcl11b fl/fl dLck-iCre mice at a 1:1 ratio. Recipient mice were then left for a minimum of 8 weeks (the first two of which were on antibiotics), at which point they were used for experimentation.
Cytokine stimulation for intracellular flow cytometry. For detection of cytokines by intracellular flow cytometry, cells were cultured at 37°C and 5% CO 2 for 4 h in IMDM media containing PMA (20 ng/ml) and Ionomycin (1 µg/ml). Brefeldin A (10 µg/ml) was added after 1 h. After incubation, cells were washed and stained with Fixable viability dye (Affymetrix) and surface markers. Cells were then fixed and permeabilized with Foxp3 Fix/Perm kit (Affymetrix, #00-5521), then subsequently stained for cytokines.
Flow cytometry. Flow cytometry was performed on an BD LSR II, with data acquired using BD FACS DIVA software. All data were analyzed using FlowJo (TreeStar).
Antibodies. The antibodies used either for staining for flow cytometry or for ChIPseq and ChIP-PCR are shown in Table 1 .
Statistical analyses. For non-sequencing experiments, differences between groups were calculated by a two-tailed Student's t-test assuming unequal variance. For RNA-Seq experiments, significance was calculated by DeSeq2 with a false discover rate (FDR) cutoff of 0.05. For ATAC-Seq experiments, significant differences in enrichment between peaks was determined using an optimized MANorm script 64, 65 with the cutoff set at a minimum fold-change of 2 and significance of p < 0.05.
Data availability. RNA-seq, ChIP-seq, and ATAC-seq data shown in this study have been deposited in the Gene Expression Omnibus (GEO) database with accession GSE99599 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE99599).
All other relevant data and reagents are available from the authors.
